SCHEMBL17792533

SCHEMBL17792533

CC(=O)NCc1c(-c2ccccc2)[nH]n(C)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ MTNR1A P48039 5/20 0.41
▸ ELANE P08246 1/20 0.39
▸ CYP1A2 P05177 3/20 0.38
▸ CYP3A4 P08684 3/20 0.38
▸ CYP2D6 P10635 2/20 0.38
▸ HTR2A P28223 2/20 0.38
▸ HTR2C P28335 2/20 0.38
▸ HTR2B P41595 2/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ MTNR1B P49286 3/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ MAT2A P31153 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.36
▸ CYBB P04839 1/20 0.36
▸ NOX4 Q9NPH5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17792536 0.86 CSNK1A1 (0.38) KDM4EALDH1A1ELANECYP1A2CYP3A4
SCHEMBL17789019 0.85 KDM4E (0.45) KDM4EALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL23399055 0.77 ALDH1A1 (0.53) KDM4EALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL19391175 0.75 KDM4E (0.39) KDM4EALDH1A1
SCHEMBL23401541 0.75 CYBB (0.59) KDM4EALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL17792562 0.74 CYP1A2 (0.34) KDM4EALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL23403012 0.74 ALDH1A1 (0.49) KDM4EALDH1A1ELANECYP1A2CYP3A4
SCHEMBL11375319 0.73 KDM4E (0.59) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL23402789 0.72 CYBB (0.50) KDM4EALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL17792532 0.72 CYP1A2 (0.33) ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170217941-A1 SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS Epizyme, Inc. 2017-08-03 — — US disclosed
US-9624205-B2 Substituted 6,5-fused bicyclic heteroaryl compounds Epizyme, Inc. (US) 2017-04-18 — — US disclosed
US-20160152604-A1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS Epizyme, Inc. 2016-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152604-A1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A5, PAICS KDM4E 1368/4885ALDH1A1 552/4885MTNR1A 1946/4885
US-20170217941-A1 SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS BCOR, CYP2B6, AHR KDM4E 860/4885ALDH1A1 737/4885MTNR1A 2252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback